Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapeutic products for cancer and chronic degenerative diseases (e.g., spinal cord injury, heart failure) based on telomerase and human embryonic stem cell (hESC) technologies. The company has no approved products on the market and relies on research and development activities, collaborative agreements, and licensing revenues.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2007 |
|---|---|---|---|
| Total Revenues | $367 | $2,259 | $2,935 |
| Net Loss | $(17,151) | $(44,389) | $(25,652) |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.57) | $(0.40) |
| Operating Expenses | $18,301 | $51,600 | $51,438 |
| Research & Development (R&D) | $14,208 | $39,435 | $39,613 |
| Cash and Cash Equivalents (Sep 30, 2008) | $121,807 | ||
| Marketable Securities (Sep 30, 2008) | $52,537 | ||
| Total Liquidity (Cash + Securities) | $174,344 | ||
| Accumulated Deficit (Sep 30, 2008) | $(489,261) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues for the nine months ended September 30, 2008, decreased to $2.26 million from $2.94 million in the prior year period. This was driven by a decrease in license fee revenues (down from $2.34 million to $2.02 million) and collaborative agreement revenues (down from $0.60 million to $0.24 million).
- Increased Net Loss: Net loss for the nine-month period increased significantly to $44.4 million from $25.7 million in 2007. This increase is primarily attributable to a decrease in interest income (due to lower rates and balances) and the absence of a $14.5 million unrealized gain on derivatives recorded in the prior year.
- R&D Expenses: R&D expenses remained relatively flat for the nine-month period ($39.4 million vs. $39.6 million), though the third quarter saw an increase due to the timing of $2.1 million in drug product purchases for clinical trials.
- Derivative Valuation: The company recorded an unrealized gain of $0.74 million on derivatives for the nine months ended September 30, 2008, compared to a gain of $14.5 million in the same period in 2007.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Needs: Management estimates existing capital resources and interest income will fund operations through at least December 2009. However, the company anticipates needing substantial additional capital in the future to fund operations and product development, likely through strategic collaborations or equity financings.
- Clinical Holds: The FDA placed a clinical hold on the company's Investigational New Drug (IND) application for GRNOPC1 (hESC-derived oligodendrocyte progenitor cells) for the treatment of acute spinal cord injury. Clinical trials cannot commence without FDA authorization.
- Joint Venture Restructuring: In August 2008, Geron exchanged its equity interest in Start Licensing, Inc. for equity in ViaGen, Inc. Geron also provided a $1.5 million convertible loan to ViaGen in September 2008.
- Key Risks:
- Regulatory Uncertainty: Delays or failures in obtaining FDA approvals for product candidates (GRN163L, GRNVAC1, GRNOPC1) could materially harm the business.
- Intellectual Property: Ongoing patent oppositions and reexaminations (e.g., with Pharmexa in Europe and Consumer Watchdog regarding WARF patents) create uncertainty regarding proprietary rights.
- Financial Sustainability: The company has a history of losses and an accumulated deficit of $489.3 million. Continued losses may impair the ability to sustain operations without additional financing.
- Market Acceptance: Ethical and social concerns regarding human embryonic stem cell research could impact market acceptance and stock price.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $174.3 million liquidity position to fund operations through the projected December 2009 date, considering potential delays in clinical trials.
- GRNOPC1 Clinical Hold: Monitor the status of the FDA clinical hold on the spinal cord injury therapy and the timeline for resolution.
- Patent Litigation Status: Track the outcomes of the European patent oppositions with Pharmexa and the appeal regarding the WARF embryonic stem cell patents.
- Revenue Recognition: Review the sustainability of license fee revenues, noting the one-time $1.5 million milestone payment recognized in 2008 related to the Exeter Life Sciences agreement.
- Derivative Liabilities: Assess the impact of fair value adjustments on derivative liabilities (warrants/options) on future earnings volatility.